Rasagiline and Parkinson's disease

November 2009
Internal Medicine Alert;Nov2009 Pharmacology Watch Supp, p2
The article reports discusses the result of a study which suggests that rasagiline may reduce the progression of Parkinson's disease.


Related Articles

  • Editorial: Parkinson's disease: cell vulnerability and disease progression. Blesa, Javier; Lanciego, Jose L.; Obeso, Jose A. // Frontiers in Neuroanatomy;Sep2015, Vol. 9, p1 

    An introduction is presented in which the editor discusses various reports within the issue on topics including Parkinson's disease (PD), neurodegeneration, and disease progression.

  • Blink i maseter inhibitorni refleks kod Parkinsonove bolesti. Stamenović, Jelena; Djurić, Stojanka; Djurić, Vanja // Vojnosanitetski Pregled: Military Medical & Pharmaceutical Journ;Mar2010, Vol. 67 Issue 3, p203 

    Background/Aim. Idiopathic Parkinson's disease (PD) is a chronic, progressive, neurodegenerative disorder with prevalence from 60 to 187 per 100 000 persons in general population. The aim of the study was to determine the abnormalities of the blink reflex (BR) and the masseter inhibitory reflex...

  • Current and Future Therapeutic Strategies for Parkinson's Disease. Outeiro, Tiago Fleming; Ferreira, Joaquim // Current Pharmaceutical Design;12/1/2009, Vol. 15 Issue 34, p3968 

    The heterogeneity of symptoms and disease progression observed in synucleinopathies, of which Parkinson's disease (PD) is the most common representative, poses large problems for its treatment and for the discovery of novel therapeutics. The molecular basis for pathology is currently unclear,...

  • An update on the management of young-onset Parkinson's disease. Klepac, Nataša; Habek, Mario; Adamec, Ivan; Barušic, Anabella Karla; Bach, Ivo; Margetic, Eduard; Lušic, Ivo // Degenerative Neurological & Neuromuscular Disease;2013, Vol. 3, p53 

    In the text that follows, we review the main clinical features, genetic characteristics, and treatment options for Parkinson's disease (PD), considering the age at onset. The clinical variability between patients with PD points at the existence of subtypes of the disease. Identification of...

  • Rasegiline and Parkinsen's disease.  // Alternative Medicine Alert;Nov2009 Pharmacology Watch Supp, p2 

    The article discusses research on the efficacy of rasagiline in slowing the progression of Parkinson's disease. It references a study published in the 2009 issue of the "New England Journal of Medicine." The study included 1,176 patients with untreated Parkinson's disease who were randomized to...

  • Treatment Strategies for Parkinson's Disease. Morgan, John C. // Journal of Managed Care Medicine;2013, Vol. 16 Issue 4, p81 

    No abstract available.

  • How do cognitive and axial motor signs correlate in Parkinson’s disease? A 6-year prospective study. Gago, Miguel Fernandes; Garrett, M. C.; Fonseca, M. R.; Rosas, M. J.; Simões, M.; Vieira, S.; Botelho, F. // Journal of Neurology;Oct2009, Vol. 256 Issue 10, p1655 

    Impairment of Parkinson’s disease (PD) axial motor signs (AMS) has been described as a risk factor for dementia. Executive dysfunction is an important feature in recently proposed clinical diagnostic criteria for PD dementia. To clarify the relationship between AMS progression and...

  • Clinical problems in late-stage Parkinson's disease. Gershanik, Oscar S. // Journal of Neurology;Nov2010, Vol. 257, p288 

    dvanced Parkinson's disease patients require for their care the participation of a multidisciplinary team. Particularly in the late stages of the disease, motor complications due both to medication and to progression of the disease, together with non-motor complications, add to the complexity of...

  • Upstream deregulation of calcium signaling in Parkinson's disease. Rivero-Ríos, Pilar; Gómez-Suaga, Patricia; Fdez, Elena; Hilfiker, Sabine // Frontiers in Molecular Neuroscience;Jun2014, Vol. 7, p1 

    Parkinson's disease (PD) is a major health problem affecting millions of people worldwide. Recent studies provide compelling evidence that altered Ca2+ homeostasis may underlie disease pathomechanism and be an inherent feature of all vulnerable neurons. The downstream effects of altered Ca2+...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics